Back to discover

Protein / target

Protachykinin-1

Encoded byTAC1P20366Homo sapiensSwiss-Prot
UniProt: P20366Ensembl: ENSG00000006128HGNC: HGNC:11517NCBI Gene: 6863
Small-molecule tractable
Druggability
Structure with Ligand
1
Research papers

Protein at a glance

Biological role

Substance P receptor binding

Strongest disease association

Risk-taking behaviour

Via encoding gene TAC1 · Genetic evidence · score 0.65

Research activity

Emerging research

1 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Tachykinins are active peptides which excite neurons, evoke behavioral responses, are potent vasodilators and secretagogues, and contract (directly or indirectly) many smooth muscles

Subcellular location

Secreted
Domains and Gene Ontology detail (32)

Gene Ontology

  • Caxon
  • Cextracellular region
  • Cextracellular space
  • Cneuronal cell body
  • Cneuronal dense core vesicle
  • Csynapse
  • Fsubstance P receptor binding
  • Padenylate cyclase-activating G protein-coupled receptor signaling pathway
  • Passociative learning
  • Pcell-cell signaling
  • Pchemical synaptic transmission
  • Pdetection of abiotic stimulus

129 aa · 15 kDa · 4 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Inhibitory neurotransmissionGOCell migrationGOImmune signallingGO
View supporting evidence

Inhibitory neurotransmission

  • ·positive regulation of synaptic transmission, GABAergic

Cell migration

  • ·positive regulation of epithelial cell migration

Immune signalling

  • ·inflammatory response
  • ·positive regulation of acute inflammatory response

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene TAC1

Gene-level evidence surfaced through the gene TAC1that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Risk-taking behaviour
0.65Moderately supported

Genetic evidence dominant · Open Targets 0.39

Smoking cessation
0.57Moderately supported

Genetic evidence dominant · Open Targets 0.35

Alcohol drinking
0.41Limited support

Genetic evidence dominant · Open Targets 0.24

Urolithiasis
0.40Limited support

Genetic evidence dominant · Open Targets 0.24

Protozoan Infections
0.39Limited support

Genetic evidence dominant · Open Targets 0.24

View evidence synthesis (5)
Risk-taking behaviourModerately supported
0.65
agreement 0.53–0.77
Genetic100%

Open Targets aggregate 0.39 · 1 independent evidence family

Smoking cessationModerately supported
0.57
agreement 0.45–0.69
Genetic100%

Open Targets aggregate 0.35 · 1 independent evidence family

Alcohol drinkingLimited support
0.41
agreement 0.27–0.54
Genetic97%Literature3%

Open Targets aggregate 0.24 · 2 independent evidence families

UrolithiasisLimited support
0.40
agreement 0.28–0.52
Genetic100%

Open Targets aggregate 0.24 · 1 independent evidence family

Protozoan InfectionsLimited support
0.39
agreement 0.27–0.51
Genetic100%

Open Targets aggregate 0.24 · 1 independent evidence family

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Risk-taking behaviour0.39
Smoking cessation0.35
Alcohol drinking0.24
Urolithiasis0.24
Protozoan Infections0.24
Attention Deficit Disorder with Hyperactivity0.22
Substance-Related Disorders0.22

Tractability

Small molecules — Emerging

Feasibility evidence (structure with ligand) — no clinical-stage drug of this modality recorded.

Antibodies — Emerging

Feasibility evidence (go cc high conf and uniprot loc med conf) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (4)
SM · Structure with LigandAB · GO CC high confAB · UniProt loc med confAB · UniProt SigP or TMHMM

Raw Open Targets tractability assessment buckets, by modality.

Research activity

1 papers · to 2024

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Substance P's Impact on Chronic Pain and Psychiatric Conditions-A Narrative Review.17 cites

Humes C · International journal of molecular sciences · 2024

Recent

Substance P's Impact on Chronic Pain and Psychiatric Conditions-A Narrative Review.

Humes C · International journal of molecular sciences · 2024

Europe PMC papers linked directly to this protein.